Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene(EGFR)-mutations in first-line for advanced non-small cell lung cancer

The introduction of first-or second-generation epidermal growth factor receptor gene(EGFR)tyrosine kinase inhibitors(TKIs)in chemonaive patients with advanced non-small cell lung cancer(NSCLC)has radically changed the treatment in this molecular subgroup,with an improvement in progression-free survival(PFS)compared to standard chemotherapy[1].